Gut microbiota in human metabolic health and disease

Publikation: Bidrag til tidsskriftReviewfagfællebedømt

Standard

Gut microbiota in human metabolic health and disease. / Fan, Yong; Pedersen, Oluf.

I: Nature Reviews. Microbiology, Bind 19, 2021, s. 55-71.

Publikation: Bidrag til tidsskriftReviewfagfællebedømt

Harvard

Fan, Y & Pedersen, O 2021, 'Gut microbiota in human metabolic health and disease', Nature Reviews. Microbiology, bind 19, s. 55-71. https://doi.org/10.1038/s41579-020-0433-9

APA

Fan, Y., & Pedersen, O. (2021). Gut microbiota in human metabolic health and disease. Nature Reviews. Microbiology, 19, 55-71. https://doi.org/10.1038/s41579-020-0433-9

Vancouver

Fan Y, Pedersen O. Gut microbiota in human metabolic health and disease. Nature Reviews. Microbiology. 2021;19:55-71. https://doi.org/10.1038/s41579-020-0433-9

Author

Fan, Yong ; Pedersen, Oluf. / Gut microbiota in human metabolic health and disease. I: Nature Reviews. Microbiology. 2021 ; Bind 19. s. 55-71.

Bibtex

@article{852bd44505674b0e924aeb4eb14ab9e2,
title = "Gut microbiota in human metabolic health and disease",
abstract = "Observational findings achieved during the past two decades suggest that the intestinal microbiota may contribute to the metabolic health of the human host and, when aberrant, to the pathogenesis of various common metabolic disorders including obesity, type 2 diabetes, non-alcoholic liver disease, cardio-metabolic diseases and malnutrition. However, to gain a mechanistic understanding of how the gut microbiota affects host metabolism, research is moving from descriptive microbiota census analyses to cause-and-effect studies. Joint analyses of high-throughput human multi-omics data, including metagenomics and metabolomics data, together with measures of host physiology and mechanistic experiments in humans, animals and cells hold potential as initial steps in the identification of potential molecular mechanisms behind reported associations. In this Review, we discuss the current knowledge on how gut microbiota and derived microbial compounds may link to metabolism of the healthy host or to the pathogenesis of common metabolic diseases. We highlight examples of microbiota-targeted interventions aiming to optimize metabolic health, and we provide perspectives for future basic and translational investigations within the nascent and promising research field.In this Review, Fan and Pedersen discuss how the gut microbiota and derived microbial compounds may contribute to human metabolic health and to the pathogenesis of common metabolic diseases, and highlight examples of microbiota-targeted interventions aiming to optimize metabolic health.",
keywords = "FATTY LIVER-DISEASE, GLUCAGON-LIKE PEPTIDE-1, INTESTINAL MICROBIOTA, INSULIN-RESISTANCE, CARDIOVASCULAR-DISEASE, GLUCOSE-HOMEOSTASIS, COMMENSAL BACTERIA, WIDE ASSOCIATION, SERUM METABOLOME, DONOR FECES",
author = "Yong Fan and Oluf Pedersen",
year = "2021",
doi = "10.1038/s41579-020-0433-9",
language = "English",
volume = "19",
pages = "55--71",
journal = "Nature Reviews. Microbiology",
issn = "1740-1526",
publisher = "nature publishing group",

}

RIS

TY - JOUR

T1 - Gut microbiota in human metabolic health and disease

AU - Fan, Yong

AU - Pedersen, Oluf

PY - 2021

Y1 - 2021

N2 - Observational findings achieved during the past two decades suggest that the intestinal microbiota may contribute to the metabolic health of the human host and, when aberrant, to the pathogenesis of various common metabolic disorders including obesity, type 2 diabetes, non-alcoholic liver disease, cardio-metabolic diseases and malnutrition. However, to gain a mechanistic understanding of how the gut microbiota affects host metabolism, research is moving from descriptive microbiota census analyses to cause-and-effect studies. Joint analyses of high-throughput human multi-omics data, including metagenomics and metabolomics data, together with measures of host physiology and mechanistic experiments in humans, animals and cells hold potential as initial steps in the identification of potential molecular mechanisms behind reported associations. In this Review, we discuss the current knowledge on how gut microbiota and derived microbial compounds may link to metabolism of the healthy host or to the pathogenesis of common metabolic diseases. We highlight examples of microbiota-targeted interventions aiming to optimize metabolic health, and we provide perspectives for future basic and translational investigations within the nascent and promising research field.In this Review, Fan and Pedersen discuss how the gut microbiota and derived microbial compounds may contribute to human metabolic health and to the pathogenesis of common metabolic diseases, and highlight examples of microbiota-targeted interventions aiming to optimize metabolic health.

AB - Observational findings achieved during the past two decades suggest that the intestinal microbiota may contribute to the metabolic health of the human host and, when aberrant, to the pathogenesis of various common metabolic disorders including obesity, type 2 diabetes, non-alcoholic liver disease, cardio-metabolic diseases and malnutrition. However, to gain a mechanistic understanding of how the gut microbiota affects host metabolism, research is moving from descriptive microbiota census analyses to cause-and-effect studies. Joint analyses of high-throughput human multi-omics data, including metagenomics and metabolomics data, together with measures of host physiology and mechanistic experiments in humans, animals and cells hold potential as initial steps in the identification of potential molecular mechanisms behind reported associations. In this Review, we discuss the current knowledge on how gut microbiota and derived microbial compounds may link to metabolism of the healthy host or to the pathogenesis of common metabolic diseases. We highlight examples of microbiota-targeted interventions aiming to optimize metabolic health, and we provide perspectives for future basic and translational investigations within the nascent and promising research field.In this Review, Fan and Pedersen discuss how the gut microbiota and derived microbial compounds may contribute to human metabolic health and to the pathogenesis of common metabolic diseases, and highlight examples of microbiota-targeted interventions aiming to optimize metabolic health.

KW - FATTY LIVER-DISEASE

KW - GLUCAGON-LIKE PEPTIDE-1

KW - INTESTINAL MICROBIOTA

KW - INSULIN-RESISTANCE

KW - CARDIOVASCULAR-DISEASE

KW - GLUCOSE-HOMEOSTASIS

KW - COMMENSAL BACTERIA

KW - WIDE ASSOCIATION

KW - SERUM METABOLOME

KW - DONOR FECES

U2 - 10.1038/s41579-020-0433-9

DO - 10.1038/s41579-020-0433-9

M3 - Review

C2 - 32887946

VL - 19

SP - 55

EP - 71

JO - Nature Reviews. Microbiology

JF - Nature Reviews. Microbiology

SN - 1740-1526

ER -

ID: 250071671